Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Reports First Quarter 2021 Financial Results
May 04, 2021 07:30 ET | Kaleido Biosciences
--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109’s potential to reduce healthcare utilization and recovery time; initiating IND application to support further...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT™) in Preventing Febrile Neutropenia
April 20, 2021 07:30 ET | Kaleido Biosciences
LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit
April 15, 2021 07:30 ET | Kaleido Biosciences
LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Reports Positive Results from Non-IND Study Demonstrating a Reduction in COVID-19 Related Healthcare Utilization and Recovery Time in Patients with Mild-to-Moderate COVID-19 and One or More Comorbidity
March 24, 2021 07:00 ET | Kaleido Biosciences
KB109 demonstrated favorable safety and tolerability profile Kaleido intends to file an Investigational New Drug (IND) application, with the goal of advancing KB109 directly into a pivotal...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results
March 03, 2021 07:35 ET | Kaleido Biosciences
Topline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021 KB295 study in patients with ulcerative colitis remains on track with topline data anticipated mid-year 2021 LEXINGTON,...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Present at Chardan’s 3rd Annual Microbiome Medicines Summit
March 01, 2021 07:30 ET | Kaleido Biosciences
LEXINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces the Exercise of the Underwriters’ Option to Purchase Additional Shares of Common Stock
February 11, 2021 13:11 ET | Kaleido Biosciences
LEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
February 03, 2021 22:03 ET | Kaleido Biosciences
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Proposed Public Offering of Common Stock
February 03, 2021 16:10 ET | Kaleido Biosciences
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference
January 20, 2021 07:30 ET | Kaleido Biosciences
LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone...